The Science

"The good thing about science is that it’s
true whether or not you believe in it."
-Neil deGrasse Tyson

References

1. A. C. Bradford, W. D. Bradford, A. Abraham, G. Bagwell Adams, Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population. JAMA Intern Med 178, 667-672 (2018).

2. Y. Shi, Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend 173, 144-150 (2017).

3. H. Abramovici, Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids. 2013. (https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/information-medical-practitioners/information-health-care-professionals-cannabis-marihuana-marijuana-cannabinoids.html, accessed June 5, 2018).

4. P. G. Fine, M. J. Rosenfeld, The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J 4, e0022 (2013).

5. M. A. Huestis, Human cannabinoid pharmacokinetics. Chem Biodivers 4, 1770-1804 (2007).

6. Z. Fisar, Phytocannabinoids and endocannabinoids. Curr Drug Abuse Rev 2, 51-75 (2009).

7. How Cannabidiol Works, (https://everythinghempoil.com/how-cbd-works/, accessed August 8, 2018)

8. V. Di Marzo, F. Piscitelli, The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics 12, 692-698 (2015).

9. D. Baker, G. Pryce, The endocannabinoid system and multiple sclerosis. Curr Pharm Des 14, 2326-2336 (2008).

10. M. R. Pazos, O. Sagredo, J. Fernandez-Ruiz, The endocannabinoid system in Huntington’s disease. Curr Pharm Des 14, 2317-2325 (2008).

11. S. Zou, U. Kumar, Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci 19, (2018).

12. E. M. Blessing, M. M. Steenkamp, J. Manzanares, C. R. Marmar, Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics 12, 825-836 (2015).

13. V. Di Marzo, L. De Petrocellis, Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci 367, 3216-3228 (2012).

14. L. De Petrocellis et al., Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163, 1479-1494 (2011).

15. L. De Petrocellis et al., Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf) 204, 255-266 (2012).

16. J. C. Ho, C. H. Lee, TRP channels in skin: from physiological implications to clinical significances. Biophysics (Nagoya-shi) 11, 17-24 (2015).

17. H. R. Ross, I. Napier, M. Connor, Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem 283, 16124-16134 (2008).

18. S. E. O’Sullivan, Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152, 576-582 (2007).

19. C. Scuderi, L. Steardo, G. Esposito, Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARgamma involvement. Phytother Res 28, 1007-1013 (2014).

20. P. J. Robson, Therapeutic potential of cannabinoid medicines. Drug Test Anal 6, 24-30 (2014).

21. T. W. Klein, Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5, 400-411 (2005).

22. E. P. Baron, Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It’s Been. Headache 55, 885-916 (2015).

23. G. D’Souza et al., Medicinal and recreational marijuana use among HIV-infected women in the Women’s Interagency HIV Study (WIHS) cohort, 1994-2010. J Acquir Immune Defic Syndr 61, 618-626 (2012).

24. G. Lafaye, L. Karila, L. Blecha, A. Benyamina, Cannabis, cannabinoids, and health. Dialogues Clin Neurosci 19, 309-316 (2017).

25. D. I. Abrams, M. Guzman, Cannabis in cancer care. Clin Pharmacol Ther 97, 575-586 (2015).

26. C. Pozzilli, Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Rev Neurother 13, 49-54 (2013).

27. W. G. Notcutt, Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis. Neurotherapeutics 12, 769-777 (2015).

28. I. Lotan, T. A. Treves, Y. Roditi, R. Djaldetti, Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol 37, 41-44 (2014).

29. J. Maroon, J. Bost, Review of the neurological benefits of phytocannabinoids. Surg Neurol Int 9, 91 (2018).

30. D. M. Morabito, P. Soyster, S. Ramey-Wright, K. Belendiuk, M. Bonn-Miller, A Review of Recent Advances in the Therapeutic Uses of Secondary Cannabinoids. (2016), vol. 3, pp. 230-238.

31. Z. Atakan, Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2, 241-254 (2012).

32. A. A. Izzo, Cannabinoids and intestinal motility: welcome to CB2 receptors. Br J Pharmacol 142, 1201-1202 (2004).

33. A. M. Malfait et al., The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 97, 9561-9566 (2000).

34. P. F. Sumariwalla et al., A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 50, 985-998 (2004).

35. R. Mathison, W. Ho, Q. J. Pittman, J. S. Davison, K. A. Sharkey, Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 142, 1247-1254 (2004).

36. S. C. Black, Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 5, 389-394 (2004).

37. J. Foulds, M. Burke, M. Steinberg, J. M. Williams, D. M. Ziedonis, Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 9, 39-53 (2004).

38. A. C. Howlett et al., Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47 Suppl 1, 345-358 (2004).

39. J. Tam et al., Endocannabinoids in liver disease. Hepatology 53, 346-355 (2011).

40. C. W. Michalski et al., Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer 122, 742-750 (2008).

41. O. Ofek et al., Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 103, 696-701 (2006).

42. National Academies of Sciences, Engineering, and Medicine, The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. (The National Academies Press, Washington, DC, 2017),https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state, accessed June 10, 2018.

43. J. Sachs, E. McGlade, D. Yurgelun-Todd, Safety and Toxicology of Cannabinoids. Neurotherapeutics 12, 735-746 (2015).

44. K. Iffland, F. Grotenhermen, An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res 2, 139-154 (2017).

45. World Health Organization, Cannabidiol (CBD) Pre-Review Report. Agenda Item 5.2. 2017. (http://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdf, accessed June 5, 2018).

46. C. M. Andre, J. F. Hausman, G. Guerriero, Cannabis sativa: The Plant of the Thousand and One Molecules. Front Plant Sci 7, 19 (2016).

47. G. Skoglund, M. Nockert, B. Holst, Viking and early Middle Ages northern Scandinavian textiles proven to be made with hemp. Sci Rep 3, 2686 (2013).

48. N. R. Ryz, D. J. Remillard, E. B. Russo, Cannabis Roots: A Traditional Therapy with Future Potential for Treating Inflammation and Pain. Cannabis Cannabinoid Res 2, 210-216 (2017).

49. S. Pain, A potted history. Nature 525, S10 (2015).

50. BBC, Timeline: the use of cannabis (http://news.bbc.co.uk/2/hi/programmes/panorama/4079668.stm, accessed May 18, 2018)

51. W. Peschel, Quality Control of Traditional Cannabis Tinctures: Pattern, Markers, and Stability. Sci Pharm 84, 567-584 (2016).

52. W. B. O’Shaughnessy, On the Preparations of the Indian Hemp, or Gunjah: Cannabis Indica Their Effects on the Animal System in Health, and their Utility in the Treatment of Tetanus and other Convulsive Diseases. Provincial Medical Journal and Retrospect of the Medical Sciences 5, 363-369 (1843).

53. S. Siff, The Illegalization of Marijuana: A Brief History, (http://origins.osu.edu/article/illegalization-marijuana-brief-history, accessed May 18, 2018)

54. A. Hathaway, The Legal History and Cultural Experience of Cannabis, in Visions, (2009), vol. 5, issue 4, pp. 12-13(http://www.heretohelp.bc.ca/sites/default/files/visions_cannabis.pdf, accessed August 24, 2018).

55. Y. Shi, M. Lenzi, R. An, Cannabis Liberalization and Adolescent Cannabis Use: A Cross-National Study in 38 Countries. PLoS ONE 10, e0143562 (2015).

56. T. Coughlin-Bogue, The Word “Marijuana” Versus the Word “Cannabis”, (https://www.thestranger.com/news/2016/04/13/23948555/the-word-marijuana-versus-the-word-cannabis, accessed May 18, 2018)

57. M. B. Bridgeman, D. T. Abazia, Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. Pharmacy and Therapeutics 42, 180-188 (2017).

58. C. Reinarman, P. D. A. Cohen, H. L. Kaal, The Limited Relevance of Drug Policy: Cannabis in Amsterdam and in San Francisco. American Journal of Public Health 94, 836-842 (2004).

59. B. Fischer, S. Kuganesan, R. Room, Medical Marijuana programs: implications for cannabis control policy–observations from Canada. Int J Drug Policy 26, 15-19 (2015).